Evidence helps aHUS eculizumab access
Article No 416 2 February 2021 Vergoeding eculizumab verlengd tot eind 2025 In March 2016 the Appraisal Committee (ACP) of the…
aHUS Trials Watch 11 ( Crovalimab)
Article No. 415 1 February 2021 In a recent article (article413) about research into why specifically monoclonal antibodies (mAb) work when…
Follow up on aHUS/COVID19 JAbs Follow Up
Article No. 414 28 January 2021 A further update on the issue of aHUS and COVID 19 vaccinations from the author’s…
BB5.1 aHUS connection to c.3643C>G; p. Arg1215Gly
Article No 413 23 January 2021 Very few people have heard of BB5.1 nor even c.3643C>G; p. Arg1215Gly. Yet both are of…
aHUS Diagnosis Process tremendous response
Article No 412 21 January 2021 The 19th January 2021 has passed and the aHUS Diagnosis Process Study Questionnaire has now…
aHUS and COVID19 vaccinations
Article No. 411 16 January 2021 COVID 19 dominates healthcare throughout the world. It dominates politics. It is in the news,…
Hitting the aHUS Ground Running
Article No. 409 9 January 2021 aHUS alliance Global Action has entered the new year with global aHUS activity in full…
A day in an aHUS life
Article No. 401 11 December 2020 When it comes to those who have aHUS in their lives , everyone has some…
Withdrawal evidence patients need to know
Article No. 400 5 December 2020 Whilst on the topic of safe withdrawal from eculizumab treatment ( see previous articles 398…
- Go to the previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 24
- Go to the next page